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Two severe Class I human glucose-6-phosphate dehydrogenase (G6PD, EC1.1.1.49) mutations, G6PDWisconsin (nt1177 C→G, R393G) and
G6PDNashville (nt1178 G→A, R393H), affect the same codon, altering a residue in the dimer interface close to the “structural” NADP
+ site. These
mutations are predicted to influence interaction with the bound “structural” NADP+, long supposed to be crucial for enzyme stability.
Recombinant proteins corresponding to these mutants have been constructed, expressed and purified to homogeneity. Steady-state kinetic
parameters of the mutant enzymes were comparable to those of normal human G6PD, indicating that the mutations do not alter catalytic efficiency
drastically. However, investigations of thermostability, urea denaturation, protease digestion, and hydrophobic exposure demonstrated that G6PD
R393H is less stable than normal G6PD or R393G, and stability was more NADP+-dependent. Apoenzymes were prepared by removal of
“structural” NADP+. Again the G6PDNashville protein was markedly less stable, and its dissociation constant for “structural” NADP
+ is ∼500 nM,
about 10 times higher than values for R393G (53 nM) and normal G6PD (37 nM). These results, together with structural information, suggest that
the instability of the R393H protein, enhanced by the weakened binding of “structural” NADP+, is the likely cause of the severe clinical
manifestation observed for G6PDNashville. They do not, however, explain the basis of disease in the case of G6PDWisconsin.
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Glucose 6-phosphate dehydrogenase (G6PD, EC 1.1.1.49)
catalyses the first committed step in the pentose phosphate
pathway, generating NADPH, which protects the mature
erythrocyte cell against oxidative damage by maintaining a
high level of reduced glutathione (GSH) and assisting the action
of catalase [1–3]. G6PD deficiency accordingly manifests itself
through abnormal haematology, and is the most common human⁎ Corresponding author. Tel.: +353 1 716 6764; fax: +353 1 283 7211.
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doi:10.1016/j.bbadis.2006.06.014enzymopathy, affecting about 400million people worldwide [4].
Among about 140 different G6PD mutations identified at the
DNA level, over 60 are severe Class I mutations which cause
chronic non-spherocytic haemolytic anaemia (CNSHA) [5]. The
fact that a disease so damaging to blood cells fails to manifest
itself in more widespread disruption of metabolism is generally
taken as indicating that the problem is one of protein instability
rather than low initial activity. The non-nucleate mature
erythrocyte has to survive over several months in circulation,
but, unlike, say, hepatocytes, is unable to replace enzyme
molecules that become denatured over that time period.
It has recently become possible to interpret changes in the
DNA and amino acid sequences in terms of the solved three-
dimensional structure of the enzyme protein. Interestingly,
more than half of the known Class I mutations cluster in exon
10, which encodes residues in the dimer interface and close to
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structural features are thought to play important roles in the
stability and integrity of the active enzyme. Two naturally-
occurring Class I mutations, G6PD Wisconsin (nt 1177
C→G, R393G) [8] and G6PD Nashville (nt 1178 G→A,
R393H) [9], affect the same codon located in this important
region. It is noteworthy that the importance of this position
was already noted in advance of a structure solution for human
G6PD in a modeling study based on the solved structure of
G6PD from Leuconostoc mesenteroides [10]. In the bacterial
enzyme, possible destabilization of “structural” NADP+ is not
an issue, as this feature is missing. However, the residue in
question is at the dimer interface in both the bacterial and the
human enzyme, and in the modeling study destabilization of
the oligomeric structure was therefore postulated as the basis
for the clinical defect [10].
So far, G6PD Wisconsin (R393G) has only been reported
once, in a 7-year-old white male, without detailed biochemical
characterisation owing to insufficient blood sample. In contrast,
G6PD Nashville (R393H), first identified in USA, has also been
reported in Italy, Portugal, Poland, Mexico etc. Although
different names, Nashville, Anaheim, Calgary, and Portici,
were initially given to the G6PD variants identified, the same
codon change, leading to replacement of Arg-393 by His, has
been found at the DNA level [11–15]. Details from the reports
suggest that this mutation has recurred in unrelated patients. As a
reviewer has pointed out, the greater frequency of the Nashville
mutation probably reflects the relative ease of the C→T
transition as compared with the G→C transversion required
for theWisconsin mutation. G6PD R393Hwas reported to show
low affinity for G6P and to be extremely unstable both in vitro
and in vivo [9,11]. However, the thermolabile enzyme could be
reactivated in the presence of high concentrations of NADP+ [9].
Speculative interpretations based on molecular modeling
[10], though valuable, are no final substitute for direct
experimental evidence. The availability of the cloned human
G6PD gene and a system for expression and purification [16]
offers the possibility of direct comparison of pure mutant and
normal enzymes. Accordingly, in order to understand the
molecular mechanism underlying G6PD deficiency in these
two mutants, and possibly shed further light on the role of
“structural” NADP+, recombinant clones corresponding to the
clinical mutants, R393G and R393H, were constructed by site-
directed mutagenesis, and the expressed proteins were purified
to homogeneity for detailed functional studies and comparison
with normal, wild-type human G6PD (WT). The results reveal
marked and surprising differences in the properties of the two
mutant forms of G6PD. The extreme sensitivity to the nature
of any substitution at this position was confirmed by less
detailed studies of mutants in which R393 was replaced by E,
V, L or I.
2. Materials and methods
2.1. Materials
Restriction enzymes, calf intestinal alkaline phosphatase, DNA modifying
enzymes, and DNA markers were purchased from NEBiolabs (USA). Agarosewas from GIBCO BRL (USA). DNA Miniprep kit and Gel extraction kit were
from QIAGEN (USA). All the oligonucleotide primers for both mutagenesis and
DNA sequencing were purchased from GIBCO BRL Life Technologies Co.
(USA). 2′5′ ADP Sepharose 4B was from Amersham Biosciences (USA).
EDTA-free protease inhibitor cocktail was from Roche.
Glucose-6-phosphate, trypsin, chymotrypsin, 8-anilinonaphthalene-1-sulpho-
nic acid (ANS), and NADP+ analogues were obtained from Sigma Chemical
Company (UK). Centricon YM-50 was fromMillipore Corporation (USA). Roche
Diagnostics supplied NADP+ (grade II) and NADPH (grade I). NADP+
concentrations were determined spectrophotometrically at 260 nm
(ε260=18.0×10
3 M−1 cm−1), and NADPH at 340 nm (ε340=6.22×10
3 M−1 cm−1).
Spectrophotometric measurements were made throughout with a Cary 300
Bio UV-visible spectrophotometer. Steady-state initial rates and protein
fluorescence were measured with a Hitachi F-4500 fluorimeter. All reagents
used were analytical grade supplied by Sigma Chemical Co (USA) or BDH
(UK).
2.2. Construction of expression plasmid
All DNA manipulations were carried out by standard procedures [17]. The
recombinant plasmid pTrc/G6PD, containing the full cDNA sequence of the
normal human G6PD gene [16], was used as a template for mutagenesis. The
desired mutations in G6PD R393G and R393H, were created by megaprimer-
based site-directed mutagenesis [18,19].The two flanking primers (below) were
IMPACT NDES, generating an NdeI restriction site at the 5′ end of the gene, and
G6PD-pQE-SalI-R, creating a SalI restriction site at the 3′ end. The internal
mutagenic primers were G6PD-R393G and G6PD-R393H, with the mutagenic
base change highlighted in bold in each case.
Primer IMPACT NDES: 5′pCAGGAAACAGCATATGGCAGAGC 3′
Primer G6PD-pQE- SalI -R: 5 ′pTAGGGCGTCGACTCAGAG-
CTTGTGGGGGTTCAC 3′
Mutagenic primer G6PD-R393G: 5′CTGGTGATCGGCGTGCAGCCC 3′
Mutagenic primer G6PD-R393H: 5′AGCTGGTGATCCACGTGCAGCC-
CAA 3′
In the first-round PCR, the reaction mixture contained 0.5 μl of template
(pTrc99A/G6PD, 0.5 μg/μl), 5 μl of Cloned pfu buffer (10×), 2 μl of flanking
primer G6PD-pQE-SalI-R (10 pmol/μl), 2 μl of mutagenic primer (10 pmol/μl),
5 μl of 2 mM dNTPs, 35 μl of ddH2O, and 0.5 μl of Cloned pfu polymerase in a
final volume of 50 μl. A 5-min denaturation step at 95 °C was followed by 34
cycles of PCR amplification, each consisting of 36 s at 95 °C, 2 min at 50 °C,
1 min at 72 °C, and followed by a final extension step at 72 °C for 10 min. The
amplified PCR products were analysed by agarose gel electrophoresis, and the
putative DNA fragments containing desired mutations were purified using the
QIA quick gel extraction kit. In the second-round PCR, the product of the first-
round PCR, the megaprimer, together with primer IMPACT NDES and the
template (pTrc99A/G6PD), were used to synthesize the full-length G6PD cDNA
harbouring the mutations. Each reaction mixture contained 0.5 μl of template
(pTrc99A/G6PD, 0.5 μg/μl), 5 μl of Cloned pfu buffer (10×), 2 μl of IMPACT
NDES primer (10 pmol/μl), 2 μl of megaprimer (first-round PCR product), 5 μl
of 2 mM dNTPs, 35 μl of ddH2O, and 0.5 μl of Cloned pfu polymerase in 50 μl
final volume. PCR was run at 95 °C for 5 min, followed by 30 cycles of 36 s at
95 °C, 1 min at 55 °C, 4 min at 72 °C, and a final extension step at 72 °C for
10 min. Amplified products of the second-round PCR were analysed, purified
and then digested with NdeI and SalI. The resulting fragment was cloned into
the expression vector, pET30b, also digested with NdeI and SalI.
In an exactly similar fashion, four new mutations that have not so far been
clinically reported were also made at the same position to replace Arg 393 with
Glu, Leu, Val and Ile. In all cases DNA constructs were sequenced both to
confirm the correct incorporation of the mutation and to check for any
unintended mutations elsewhere in the gene.
2.3. Expression and purification of recombinant G6PD
Recombinant constructs with the desired mutation(s) were transformed into
competent E. coli BL21(DE3) cells, which were grown at 37 °C overnight on a
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clones containing either the entire wild-type gene or the variant cDNA insert
were separately inoculated into 5 ml LB medium with kanamycin and grown
overnight. 2 ml overnight culture was inoculated into 200 ml LB medium with
kanamycin and grown at 37 °C with shaking. When A600 of the culture reached
∼0.8, IPTG was added to a final concentration of 0.5 mM. The culture was
allowed to grow for another 5 h at 30 °C before harvesting by centrifugation.
The wild-type and mutant G6PDs were successfully purified by affinity
chromatography on 2′,5′-ADP-Sepharose 4B as described previously [20].
2.4. Initial rate measurements
Steady-state kinetic studies were carried out fluorimetrically at 25 °C [16].
The reaction buffer was 0.1 M Tris/HCl, pH 8.0, containing 0.01 M MgCl2.
NADP+ concentrations ranged from 2 to 50 μM and G6P concentrations from 40
to 1000 μM.
2.5. Stability in the presence or absence of urea
In order to study susceptibility to denaturation, the purified enzyme was first
diluted extensively so that the final concentration of free NADP+ was ∼1 μM
(75 μMNADP+ is used to elute the enzyme from the column during purification
and to stabilize during storage). Different concentrations of urea were added to
separate samples, which were then incubated at room temperature. Residual
enzyme activity was measured at intervals over a period of up to 3 h.
2.6. Protease digestion
Trypsin and chymotrypsin were used to probe proteolytic sensitivity of
G6PD WT, R393G, and R393H. G6PD samples were diluted to a final protein
concentration of 0.01 mg/ml. Trypsin (0.5 mg/ml) or chymotrypsin (0.05 mg/ml)
and different amounts of NADP+ from 1 μM to 100 μM were added to
individual samples. The mixtures were kept at room temperature and the residual
G6PD activity was measured at intervals. Control samples without protease kept
over 90% of their activity throughout the incubation.
2.7. Hydrophobic surface exposure experiment
The exposure of hydrophobic areas, a feature of a putative ‘molten-globule’
state [21], was assessed by fluorimetric assay of the binding of 8-
anilinonaphthalene-1-sulphonic acid (ANS). The protein (10 μg/ml), with
various concentrations of urea, was incubated with 20 μM ANS. A Hitachi
F-4500 spectrofluorimeter was used at a working power of 700 w. Excitation
and emission wavelengths were 350 nm and 470 nm, respectively, with a slit of
10 nm in each case.
2.8. Determination of dissociation constant of “structural” NADP+
“Structural” NADP+ was quantitatively stripped from the holoenzymes as
described [22]. In brief, “structural” NADP+ could be converted to NADPH by
adding G6P to the holoenzyme, followed by gel filtration to remove NADPH
and the remaining G6P. The resulting apoenzyme was titrated with NADP+Table 1
Yields and specific activities of recombinant human G6PD and six mutants
WT
Total enzyme activity in the crude extract from 200 ml culture (IU) 260±17
Specific activity in the crude extract (IU/mg) 2.5±0.2
Total activity of purified enzyme (IU) 130±15
Specific activity of purified enzyme (IU/mg) 180±10
Yield (%) 50±5
The total activity in the crude extract reflects both the expression level and the spe
activities reflect the true catalytic properties of each protein, and, on the other, the tota
purification.using a Hamilton microsyringe, and the fluorescence quench was monitored as
described in the same report.
2.9. Apoenzyme stability test
The apoenzymes were incubated at 37 °C, with and without 10 μMNADP+,
at a protein concentration of 10 μg/ml. Enzyme activity was followed during the
incubation by removing samples for assay.
3. Results
3.1. Enzyme preparation
Under the conditions described, 1300 IU, 1200 IU, and 1000
IU G6PD activity per litre culture were obtained for G6PD WT,
R393G, and R393H in the initial crude extract, and quite similar
figures were also obtained for the E, V, L and I mutants (Table
1). This suggests in all cases similar expression levels of
enzymes of similar activity. Following identical purification
procedures from this relatively uniform starting point, however,
the final yields of pure protein covered a wide range: the final
purification yield of G6PD R393G was about 50%, similar to
that for WT, but was much lower, at 6–7%, for R393H and
R393E. The other three mutants gave yields of 24–31%. The
purified G6PD WT and R393G showed specific activities of
around 180 IU/mg, and the three mutants R393V, R393L and
R393I also showed similar activities ranging from 166 to
181 IU/mg. Again G6PD R393H and R393E were distinctly
different, with specific activities about 25% lower, at 130–
135 IU/mg.
3.2. Steady-state kinetic parameters
Detailed kinetic measurements were made for the two
clinical mutants and WT G6PD for comparison. The Dalziel
[23] parameters of G6PD R393G and R393H (Table 2) were
derived as described for the WT enzyme from primary and
secondary plots of the initial rates [16,20]. The kcat value (1/ϕo)
of G6PD WT (275 s−1) was only slightly higher than those of
G6PD R393G (232 s−1) and G6PD R393H (192 s−1), showing
that the maximal catalytic efficiency is only moderately affected
by the mutations. However, the Km values of G6PD R393H for
G6P (ϕG6P/ϕo )and NADP
+ (ϕNADP+/ϕo) were 190 μM and
16.5 μM respectively, about four-fold and two-fold higher than
the values for the WT enzyme, implying that this mutation has
significantly affected the binding of the substrates. By contrast,R393G R393H R393E R393V R393L R393I
240±19 200±16 195±15 190±17 200±16 190±18
2.4±0.2 2.1±0.3 1.9±0.3 2.1±0.1 2.0±0.2 1.9±0.3
120±15 12±5 14±8 48±10 62±10 46±9
178±15 130±10 135±15 166±14 176±12 181±10
50±5 6±3 7±4 25±5 31±5 24±5
cific activity for each protein. After purification, on the one hand, the specific
l activity at this point is a reflection of the extent of loss through instability during
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error, unaltered.
3.3. Susceptibility to denaturation by heat or urea and to
protease digestion
Structural instability of the mutant enzyme is thought to be
the most frequent explanation for G6PD deficiency in man
and might be expected to be demonstrable in vitro. At the
physiological concentration of NADP+ (around 10 μM), T50,
the temperature at which 50% of the original activity is
retained after incubating at different temperatures for 20 min,
was about 50 °C for WT and R393G. However, the T50 of
R393H was only 40 °C under the same conditions, suggesting
that this mutant is much more thermolabile (data not shown).
G6PD WT and R393G were similarly quite stable in the
presence of 1 M urea, and began to lose activity gradually
(30–40% over 3 h) only when the concentration of urea was
increased to 1.5 M (Fig. 1). In contrast, R393H was very
susceptible to urea, and lost about 80% of its activity even
after incubating with 0.5 M urea for only 10 min. For all
three enzymes, NADP+ (10 μM) offered protection against
urea denaturation, but this was clearly only partial in the case
of R393H. Compared with G6PD WT and R393G, G6PD
R393H was also more susceptible to proteolysis both by
trypsin and by chymotrypsin (Fig. 2). Addition of NADP+
again seemed to counteract the susceptibility of all three
enzymes to proteolytic digestion in a concentration-dependent
manner.
3.4. Exposure of hydrophobic areas
Fig. 3 shows the ratio of the fluorescence of WT and
mutants, which were incubated with different concentrations of
urea for 2 h, to the fluorescence of these enzymes in the
absence of urea. The fluorescence signals of WT and the two
mutant enzymes increased and reached a maximum after
incubating with 3 M urea for 30 min (data not shown) or at 2 M
for 2 h, although each enzyme showed a different maximum
peak height at these urea concentrations. Without urea, the
fluorescence signal of R393H was about 31.4% (δF0/δFmax) of
the maximum fluorescence signal observed after incubating the
mutant with 2 M urea for 2 h. The much lower corresponding
figures for WT (19%) and R393G (9%), suggest that a larger
hydrophobic area is accessible to ANS in R393H in the absence
of urea.Table 2
Dalziel steady-state kinetic parameters
Enzyme ϕo (s) ϕNADP+
(μM s)
ϕG6P
(μM s)
ϕNADP+G6P
(μM2 s)
ϕNADP+
ϕNADP+
WT 0.00366±0.00023 0.0259±0.0041 0.191±0.021 1.61±0.22 58.0±
R393G 0.0043±0.00032 0.0402±0.0092 0.288±0.018 3.47±0.59 84.8±
R393H 0.0052±0.0005 0.0853±0.0067 0.992±0.11 12.1±0.57 142.0±
The table shows the four constants of the reciprocal initial-rate equation [23] as estima
corresponding of kcat values and the true Km values for both substrates are also listed.
and from different enzyme preparations.3.5. Dissociation constant of “structural” NADP+ and stability
In a recent study [22] we have found that “structural”
NADP+ may be removed from G6PD to form an active
apoenzyme. The addition of NADP+ quenches the intrinsic
fluorescence of the apoenzyme, making it possible to estimate a
dissociation constant for the tight binding of the “structural”
NADP+. Similar experiments were carried out with the two
mutant enzymes, and, from the fluorescence titration, the
dissociation constant of R393H was around 500 nM, almost 14
times higher than that of the WT enzyme (37 nM), indicating
that binding of “structural” NADP+ in this mutant is
considerably impaired. In this case the use of relatively high
coenzyme concentrations allowed the Kd to be readily estimated
from a Scatchard plot (not shown) of the data. However, for
G6PD R393G the dissociation constant of “structural” NADP+
was much lower, necessitating an iterative fit of the data, since
binding to the enzyme significantly depletes the concentration
of free NADP+. An excellent fit was obtained for a Kd value of
53 nM, on the assumption of 97.2% quenching of the
fluorescence of the free enzyme. (For 12 points the value of
Fcalc/Factual was randomly scattered either side of 1.000, with a
maximum value of 1.005 and a minimum value of 0.997). This
figure for Kd is only moderately elevated relative to that for the
normal enzyme.
Previous studies showed that “structural” NADP+ is
important for the stability and integrity of the active enzyme
[6,24–28]. In the current study, the WT apoenzyme lost activity
rapidly when incubated at 37 °C: after 30 h at 37 °C, only 10%
enzyme activity remained [22]. Compared with theWTenzyme,
G6PD R393H without NADP+ was even less stable, losing all
activity after 20 h, in agreement with the original observations
of Beutler et al. [9] and Filosa et al. [11]. However, under the
conditions used, no significant difference in stability between
R393G and WT could be observed. In the presence of 10 μM
NADP+, all the enzymes appeared to be more stable, but there
was still a clear differentiation between the two mutants: WT
and R393G remained active for 1 month at 37 °C, whereas
R393H lost all activity after 9 days of incubation (data not
shown).
4. Discussion
G6PD deficiencies are usually recognized through haema-
tological studies, and the classification of clinical severity is
based on the levels of G6PD activity found in red cells.G6P/
(μM)
ϕNADP+G6P/
ϕG6P(μM)
kcat
(s−1)
KmNADP+
(μM)
KmG6P
(μM)
kcat/KmNADP+
(μM−1 s−1)
kcat/KmG6P
(μM−1 s−1)
0.68 7.77±0.68 275±18 7.07±1.13 52±4 39.7±7.5 5.31±0.69
4.6 12.0±1.21 232±16 9.31±2.4 67.1±13 25.8±3.2 3.52±0.50
9.5 12.4±1.3 192±18 16.5±2.7 190±27 13.9±2.3 1.02±0.15
ted for wild-type G6PD and for the two mutant enzymes R393G and R393H. The
The parameters in each case were obtained from three independent experiments
Fig. 1. Stability of G6PD WT, R393G and R393H incubated with different concentrations of urea in the absence or presence of NADP+.
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accurate indication of alterations in Km values, but decreased
absolute levels of activity may reflect either decreased specific
activity of the mutant G6PD or else impaired folding or stability,
resulting in a lower concentration of active enzyme protein. To
resolve such ambiguities and obtain a clearer view of the
molecular basis of the enzymopathy, it is valuable to be able to
compare the purified enzymes, and recombinant expression
provides a route to substantial quantities of pure protein for such
studies.
In the present study we have focused attention on two
severe Class I mutants, G6PD Wisconsin (R393G) and G6PDNashville (R393H), in which the substituted residue is at a site
well removed from the catalytic site but close to the binding
site [6] for “structural” NADP+ between the G6PD dimer
interface and the C-terminus. It was hoped that detailed study
of these two naturally-occurring mutants, and of other
mutations at the same site, might illuminate the role of Arg
393 in the structure and function of h-G6PD and yield further
evidence regarding the significance of the “structural” NADP+
molecule.
The similar levels of recombinant expression of wild-type
G6PD and all six mutants studied clearly indicate that the
problem in the clinical cases does not lie in impaired folding.
Fig. 2. Susceptibility of G6PD WT, R393G, and R393H to trypsin in the
presence of different concentrations of NADP+.
Fig. 3. Different hydrophobic exposure areas of G6PDWT, R393G, and R393H
after incubation in different concentrations of urea for 2 h. δF and δF0 are the
fluorescence signals in the presence and absence of urea respectively.
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provide immediate evidence that two of the mutants, R393H
and R393E are considerably less stable than the others.
Although R393 is not close to the active site, it was also
necessary to check whether the mutations had affected kinetic
properties, since a small structural perturbation might
markedly impair catalytic efficiency, as in the case of
G6PD R454C (G6PD Union) and R454H (G6PD Andalus)
[20]. The specific activities of the purified proteins (Table 1)
show, however, only a moderate decrease in R393H and
R393E, with the figures for the other mutants close to that for
wild-type G6PD. A more detailed kinetic comparison of the
two clinical mutants with normal G6PD (Table 2) reveals that
the Km values for coenzyme (ϕNADP+/ϕo) and sugar
phosphate (ϕG6P/ϕo) of the R393G enzyme are 9.3 μM and67 μM, very similar to the corresponding figures for WT
enzyme (7.07 μM and 52 μM). On the other hand, the Km
values of 16.5 μM and 190 μM for NADP+ and G6P found
for R393H are considerably higher, in agreement with the
original report of a substantially increased Km for G6P with
G6PDNashville [11]. G6PD WT and R393G have quite similar
catalytic efficiencies under saturating conditions, whereas the
kcat value of G6PD R393H (192 s
−1) was about 30% lower
than that of the WT enzyme (275 s−1). This modest decrease
in catalytic efficiency is, however, clearly unlikely to be the
predominant cause of the severe disease phenotype.
A distinctive characteristic of mature non-nucleate erythro-
cytes is their inability to synthesize proteins to replace
damaged and aged enzyme molecules. Therefore, instability
of the protein is usually the key problem in G6PD deficiency.
The initial indications of instability in R393H from Table 1
were convincingly borne out by a series of studies on the
purified protein, showing that, even in the presence of a
physiological concentration of NADP+, the mutant R393H is
much more susceptible than the WT or R393G to denaturation
by heat or urea and also to proteolysis. The study with ANS
suggests that this mutant enzyme has a looser structure,
making more hydrophobic surfaces accessible to the dye
probe. In striking contrast, in all these studies the second
clinical mutant, R393G, behaved quite similarly to the normal
enzyme.
Details from the 3-D structure of human G6PDCanton imply
that the “structural” NADP+ is important in maintaining the
stability and integrity of the active enzyme [6]. Modeling shows
that Arg 393 is close to, and may interact with, the “structural”
NADP+ [6], a view supported by details from the newly-solved
crystal structures of G6P and NADP+ complexes of a truncated
G6PD mutant [29]. Arg 393 is at the end of the sheet βL in the
dimer interface (Fig. 4) and the atoms Nη1 and Nη2 of this
residue interact with the nicotinamide amide oxygen of the
“structural” NADP+. It has also been proposed that the side
chain of Arg 393 could likely form hydrogen bond or charge
interactions with other amino acids in/around the extensive β
sheets which form the dimer interface. Replacement of this
Fig. 4. Modeled 3-D structure of G6PD around amino acid 393. (a) WT, (b)
R393G, and (c) R393H.
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amide and the charge contacts would be disrupted as well (Fig.
4). This small change could affect the interplay between the
dimer interface and the “structural” NADP+, thus leading to
instability of the mutant enzymes. The replacement with glycine
thus might have been thought the more drastic of the two
clinical mutations, but the overall pattern, including the results
with E, V, L and I mutants, suggests that loss of the guanidino
group's interactions in the various hydrophobic replacements is
actually less damaging than replacement with a residue such asH or E which may form inappropriate hydrogen bond or charge
interactions.
The ability to remove “structural” NADP+ and make a
functional apoenzyme [22] allowed us to look more closely at
the importance of the additional coenzyme molecule in the
properties of the clinical mutants. It is clear that in the absence
of tightly bound NADP+ the R393H apoprotein is intrinsically
less stable than the apoprotein of normal G6PD, and this may
well be accounted for by destabilisation of the dimer interface
[10]. On the other hand, in all the stability tests, the inclusion of
NADP+ strongly stabilized the enzymes, and the Kd determina-
tion shows that the intrinsically unstable R393H protein is also
markedly impaired in its ability to bind and retain “structural”
NADP+. It is thus not only less stable but also less able to be
stabilized.
In summary, instability, enhanced by the low binding
capacity for “structural” NADP+, is clearly the main cause of
clinical enzyme deficiency in R393H, although this mutant
also shows some moderate kinetic impairment. In marked
contrast, no significant difference in the functional properties
between WT and R393G has been detected under the
experimental conditions studied so far, and the detailed studies
of this mutant protein provide no clue to the basis of a severe
phenotype. Only one case of R393G has been reported to date
with little accompanying clinical and haematological informa-
tion, and it is impossible to assess whether the observed Class I
phenotype was dependent on environmental challenge or the
individual genetic background. The biochemical analysis of
the recombinant enzyme inevitably raises a question over the
clinical classification of this mutant, although it remains
possible that subtle structural changes render the protein
vulnerable to destructive influences that are present in the
erythrocyte but missing in the artificial purity of our in vitro
experiments.
Acknowledgments
This paper is dedicated by X.-T.W. and P.C.E. to the memory
of our co-author Dr. Veronica Lam, who was lost in the Asian
tsunami after the completion of the work and during preparation
of the manuscript. We also wish to thank Dr. Margaret Adams
for commenting on the structural aspects of the paper.
This work was submitted by X.-T. W. in partial fulfillment of
the requirements for the Ph. D. degree of the University of Hong
Kong.
This work was supported by Grant HKU-7243/00M to Dr.
V.M.S. Lam from the Research Grants Council of Hong Kong.
References
[1] H.N. Kirkman, S. Galiano, G.F. Gaetani, The function of catalase-bound
NADPH, J. Biol. Chem. 262 (1987) 660–666.
[2] M.D. Scott, L. Zuo, B.H. Lubin, D.T. Chiu, NADPH, not glutathione,
status modulates oxidant sensitivity in normal and glucose-6-phosphate
dehydrogenase-deficient erythrocytes, Blood 77 (1991) 2059–2064.
[3] G.F. Gaetani, M. Rolfo, S. Arena, R. Mangerini, G.F. Meloni, A.M.
Ferraris, Active involvement of catalase during hemolytic crises of favism,
Blood 88 (1996) 1084–1088.
774 X.-T. Wang et al. / Biochimica et Biophysica Acta 1762 (2006) 767–774[4] L. Luzzatto, A. Mehta, T.J. Vulliamy, Glucose 6-phosphate dehydrogenase
deficiency, in: C.R. Scriver, A.L. Beaudet, W.S. Sly (Eds.), The Metabolic
and Molecular Bases of Inherited Disease, 8th ed., McGraw Hill, New
York, 2001, pp. 4517–4553.
[5] E. Beutler, T.J. Vulliamy, Hematologically important mutations: glucose-
6-phosphate dehydrogenase, Blood Cells Mol. Diseases 28 (2002)
93–103.
[6] S.W. Au, S. Gover, V.M. Lam, M.J. Adams, Human glucose-6-phosphate
dehydrogenase: the crystal structure reveals a structural NADP+ molecule
and provides insights into enzyme deficiency, Structure 8 (2000) 293–303.
[7] C.J. Kwok, A.C. Martin, S.W.N. Au, V.M.S. Lam, G6PDdb, an integrated
database of glucose-6-phosphate dehydrogenase (G6PD) mutations, Hum.
Mutat. 19 (2002) 217–224.
[8] E. Beutler, B. Westwood, A. Melemed, P. Dal Borgo, D. Margolis, Three
new exon 10 glucose-6-phosphate dehydrogenase mutations, Blood Cells
Mol. Diseases 21 (1995) 64–72.
[9] E. Beutler, W. Kuhl, T. Gelbart, L. Forman, DNA sequence abnormalities
of human glucose-6-phosphate dehydrogenase variants, J. Biol. Chem. 266
(1991) 4145–4150.
[10] C.E. Naylor, P. Rowland, A.K. Basak, S. Gover, P.J. Mason, J.M. Bautista,
T.J. Vulliamy, L. Luzzatto, M.J. Adams, Glucose 6-phosphate dehydro-
genase mutations causing enzyme deficiency in a model of the tertiary
structure of the human enzyme, Blood 87 (1996) 2974–2982.
[11] S. Filosa, V. Calabro, D. Vallone, V. Poggi, P. Mason, D. Pagnini, F.
Alfinito, B. Rotoli, G. Martini, L. Luzzatto, et al., Molecular basis of
chronic non-spherocytic haemolytic anaemia: a new G6PD variant (393
Arg→His) with abnormal KmG6P and marked in vivo instability, Br. J.
Haematol. 80 (1992) 111–116.
[12] T.A. Weimer, F.M. Salzano, B. Westwood, E. Beutler, Molecular
characterization of glucose-6-phosphate dehydrogenase variants from
Brazil, Hum. Biol. 65 (1993) 41–47.
[13] S. Filosa, N. Giacometti, C. Wangwei, D. De Mattia, D. Pagnini, F.
Alfinito, F. Schettini, L. Luzzatto, G. Martini, Somatic-cell selection is a
major determinant of the blood-cell phenotype in heterozygotes for
glucose-6-phosphate dehydrogenase mutations causing severe enzyme
deficiency, Am. J. Hum. Genet. 59 (1996) 887–895.
[14] T.J. Vulliamy, J.S. Kaeda, D. Ait-Chafa, R. Mangerini, D. Roper, J. Barbot,
A.B. Mehta, M. Athanassiou-Metaxa, L. Luzzatto, P.J. Mason, Clinical
and haematological consequences of recurrent G6PD mutations and a
single new mutation causing chronic nonspherocytic haemolytic anaemia,
Br. J. Haematol. 101 (1998) 670–675.
[15] G. Vaca, E. Arambula, A. Esparza, Molecular heterogeneity of glucose-6-
phosphate dehydrogenase deficiency in Mexico: overall results of a 7-year
project, Blood Cells Mol. Diseases 28 (2002) 436–444.[16] X.T. Wang, S.W.N. Au, V.M.S. Lam, P.C. Engel, Recombinant human
glucose-6-phosphate dehydrogenase. Evidence for a rapid-equilibrium
random-order mechanism, Eur. J. Biochem. 269 (2002) 3417–3424.
[17] J. Sambrook, E.F. Fritsch, T. Maniatis, Molecular Cloning, A Laboratory
Manual, Cold Spring Harbor, New York, 1989.
[18] O. Landt, H.P. Grunert, U. Hahn, A general method for rapid site-directed
mutagenesis using the polymerase chain reaction, Gene 96 (1990) 125–128.
[19] G. Sarkar, S.S. Sommer, The “megaprimer” method of site-directed
mutagenesis, BioTechniques 8 (1990) 404–407.
[20] X.T. Wang, V.M.S. Lam, P.C. Engel, Marked decrease in specific activity
contributes to disease phenotype in two human glucose 6-phosphate
dehydrogenase mutants, G6PD(Union) and G6PD(Andalus), Hum. Mutat.
26 (2005) 284.
[21] G.V. Semisotnov, N.A. Rodionova, O.I. Razgulyaev, V.N. Uversky, A.F.
Gripas, R.I. Gilmanshin, Study of the “molten globule” intermediate state
in protein folding by a hydrophobic fluorescent probe, Biopolymers 31
(1991) 119–128.
[22] X.T. Wang, V.M.S. Lam, P.C. Engel, What is the role of the second,
‘structural’ NADP+ binding site in human glucose 6-phosphate dehy-
drogenase? Properties of a native apoenzyme, Biochim. Biophys. Acta,
Protein Struct. (submitted for publication).
[23] K. Dalziel, Initial steady state velocities in the evaluation of enzyme–
coenzyme–substrate reaction mechanisms, Acta Chem. Scand. 11 (1957)
1706–1723.
[24] H.N. Kirkman, Glucose 6-phosphate dehydrogenase from human
erythrocytes: I. Further purification and characterization, J. Biol. Chem.
237 (1962) 2364–2370.
[25] H.N. Kirkman, E.M. Hendrickson, Glucose 6-phosphate dehydrogenase
from human erythrocytes: II. Subactive states of the enzyme from normal
persons, J. Biol. Chem. 237 (1962) 2371–2376.
[26] A.E. Chung, R.G. Langdon, Human erythrocyte glucose 6-phosphate
dehydrogenase: II. Enzyme–coenzyme interrelationship, J. Biol. Chem.
238 (1963) 2317–2324.
[27] L. Luzzatto, N.C. Allan, Different properties of glucose 6-phosphate
dehydrogenase from human erythrocytes with normal and abnormal
enzyme levels, Biochem. Biophys. Res. Commun. 21 (1965) 547–554.
[28] A. Bonsignore, I. Lorenzoni, R. Cancedda, A. De Flora, Distinctive
patterns of NADP binding to dimeric and tetrameric glucose 6-phosphate
dehydrogenase from human red cells, Biochem. Biophys. Res. Commun.
39 (1970) 142–148.
[29] M. Kotaka, S. Gover, L. Vandeputte-Rutten, S.W.N. Au, V.M.S. Lam, M.J.
Adams, Structural studies of glucose-6-phosphate and NADP+ binding to
human glucose-6-phosphate dehydrogenase, Acta Crystallogr. D: Biol.
Crystallogr. 61 (2005) 495–504.
